INT221386
From wiki-pain
(Difference between revisions)
(Generated page) |
(Generated page) |
||
| Line 31: | Line 31: | ||
|- | |- | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 3. | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 3.53 |
|- | |- | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.90 |
|- | |- | ||
|} | |} | ||
| Line 128: | Line 128: | ||
|} | |} | ||
{| cellspacing=2 cellpadding=2 | {| cellspacing=2 cellpadding=2 | ||
| − | | | + | | style="vertical-align: top"| |
{| cellspacing=1 cellpadding=5 align=center | {| cellspacing=1 cellpadding=5 align=center | ||
|- | |- | ||
| Line 138: | Line 138: | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[cytokine]] | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[cytokine]] | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 60 | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 60 | ||
| − | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100 | + | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100.00 |
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} | ||
|- | |- | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[antagonist]] | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[antagonist]] | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 24 | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 24 | ||
| − | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 98. | + | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 98.40 |
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} | ||
|- | |- | ||
| Line 178: | Line 178: | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Lasting pain]] | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Lasting pain]] | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 1 | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 1 | ||
| − | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 5 | + | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 5.00 |
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} | ||
|- | |- | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[anti-cytokine treatment]] | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[anti-cytokine treatment]] | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 1 | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 1 | ||
| − | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 5 | + | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 5.00 |
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} | ||
|- | |- | ||
| Line 189: | Line 189: | ||
|} | |} | ||
| | | | ||
| − | | | + | | style="vertical-align: top"| |
{| cellspacing=1 cellpadding=5 align=center | {| cellspacing=1 cellpadding=5 align=center | ||
|- | |- | ||
| Line 214: | Line 214: | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Fungal Infection]] | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Fungal Infection]] | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 3 | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 3 | ||
| − | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90. | + | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90.40 |
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}} | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}} | ||
|- | |- | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Critical Illness]] | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Critical Illness]] | ||
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2 | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2 | ||
| − | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 84 | + | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 84.00 |
| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}} | | style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}} | ||
|- | |- | ||
| Line 290: | Line 290: | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2855078 PMC2855078] | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2855078 PMC2855078] | ||
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.35 |
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.04 |
|} | |} | ||
|- | |- | ||
| Line 321: | Line 321: | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2695202 PMC2695202] | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2695202 PMC2695202] | ||
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.44 |
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.26 |
|} | |} | ||
|- | |- | ||
|} | |} | ||
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | ||
| − | | As expected, it should be pointed that <span style="background-color:#FFFF00">LPS</span>-<span style="background-color:#B0E0E6">induced</span> <span style="background-color:#FFFF00">IL-8</span> <span style="background-color:#B0E0E6">levels</span> varied among COPD patients, suggesting that <span style="background-color:#FFDEAD">epithelial cell</span> responsiveness to LPS cannot alone explain the complex inflammatory process of COPD. | + | | As expected, it should be pointed that <span style="background-color:#FFFF00">LPS</span>-<span style="background-color:#B0E0E6">induced</span> <span style="background-color:#FFFF00">IL-8</span> <span style="background-color:#B0E0E6">levels</span> varied among <span style="background-color:#FFA07A">COPD</span> patients, suggesting that <span style="background-color:#FFDEAD">epithelial cell</span> responsiveness to LPS cannot alone explain the complex <span style="background-color:#FFA07A">inflammatory</span> process of <span style="background-color:#FFA07A">COPD</span>. |
|- | |- | ||
| Line 334: | Line 334: | ||
{| cellpadding=4 cellspacing=2 | {| cellpadding=4 cellspacing=2 | ||
|- | |- | ||
| − | | <span style="color:#800000">'''LPS'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induced</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">levels</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">epithelial cell</span> | + | | <span style="color:#800000">'''LPS'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induced</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">levels</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">epithelial cell</span> associated with <span style="color:#FF0000">'''pulmonary disease'''</span> and <span style="color:#FF0000">'''inflammation'''</span> |
|- | |- | ||
|} | |} | ||
| Line 353: | Line 353: | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2214730 PMC2214730] | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2214730 PMC2214730] | ||
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 1.79 |
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.20 |
|} | |} | ||
|- | |- | ||
|} | |} | ||
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | ||
| − | | Indeed, it was found that a constitutively active mutant of human <span style="background-color:#FFFF00">TLR4</span>, transfected into a monocytic cell line, could <span style="background-color:#B0E0E6">induce</span> the activation of NF-kappaB and the <span style="background-color:#B0E0E6">expression</span> of the proinflammatory cytokines IL-1, IL-6, and <span style="background-color:#FFFF00">IL-8</span> as well as the expression of the costimulatory molecule CD80 (B7.1), which is required for the activation of naïve <span style="background-color:#FFDEAD">T lymphocytes</span> [66]. | + | | Indeed, it was found that a constitutively active mutant of human <span style="background-color:#FFFF00">TLR4</span>, transfected into a monocytic cell line, could <span style="background-color:#B0E0E6">induce</span> the activation of NF-kappaB and the <span style="background-color:#B0E0E6">expression</span> of the proinflammatory <span style="background-color:#FFA07A">cytokines</span> IL-1, IL-6, and <span style="background-color:#FFFF00">IL-8</span> as well as the expression of the costimulatory molecule CD80 (B7.1), which is required for the activation of naïve <span style="background-color:#FFDEAD">T lymphocytes</span> [66]. |
|- | |- | ||
| | | | ||
{| cellpadding=4 cellspacing=2 | {| cellpadding=4 cellspacing=2 | ||
|- | |- | ||
| − | | <span style="color:#800000">'''TLR4'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induce</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">expression</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">T lymphocytes</span> | + | | <span style="color:#800000">'''TLR4'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induce</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">expression</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">T lymphocytes</span> associated with <span style="color:#FF0000">'''cytokine'''</span> |
|- | |- | ||
|} | |} | ||
| Line 384: | Line 384: | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2817369 PMC2817369] | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2817369 PMC2817369] | ||
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.27 |
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.11 |
|} | |} | ||
|- | |- | ||
|} | |} | ||
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | ||
| − | | Indeed, it was found that a constitutively active mutant of human <span style="background-color:#FFFF00">TLR4</span>, transfected into a monocytic cell line, could <span style="background-color:#B0E0E6">induce</span> the activation of NF-kappaB and the expression of the proinflammatory cytokines IL-1, IL-6, and <span style="background-color:#FFFF00">IL-8</span> as well as the <span style="background-color:#B0E0E6">expression</span> of the costimulatory molecule CD80 (B7.1), which is required for the activation of naïve <span style="background-color:#FFDEAD">T lymphocytes</span> [66]. | + | | Indeed, it was found that a constitutively active mutant of human <span style="background-color:#FFFF00">TLR4</span>, transfected into a monocytic cell line, could <span style="background-color:#B0E0E6">induce</span> the activation of NF-kappaB and the expression of the proinflammatory <span style="background-color:#FFA07A">cytokines</span> IL-1, IL-6, and <span style="background-color:#FFFF00">IL-8</span> as well as the <span style="background-color:#B0E0E6">expression</span> of the costimulatory molecule CD80 (B7.1), which is required for the activation of naïve <span style="background-color:#FFDEAD">T lymphocytes</span> [66]. |
|- | |- | ||
| | | | ||
{| cellpadding=4 cellspacing=2 | {| cellpadding=4 cellspacing=2 | ||
|- | |- | ||
| − | | <span style="color:#800000">'''TLR4'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induce</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">expression</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">T lymphocytes</span> | + | | <span style="color:#800000">'''TLR4'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induce</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">expression</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">T lymphocytes</span> associated with <span style="color:#FF0000">'''cytokine'''</span> |
|- | |- | ||
|} | |} | ||
| Line 415: | Line 415: | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2817369 PMC2817369] | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2817369 PMC2817369] | ||
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.32 |
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.11 |
|} | |} | ||
|- | |- | ||
|} | |} | ||
{| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable" | ||
| − | | Conversely, the P2RY6 receptor antagonists, anthraquinone-sulfonic acid derivative reactive blue 2 and suramin, inhibited <span style="background-color:#FFFF00">LPS</span>-<span style="background-color:#B0E0E6">induced</span> <span style="background-color:#FFFF00">IL-8</span> <span style="background-color:#B0E0E6">production</span> by <span style="background-color:#FFDEAD">THP-1</span> cells [24]. | + | | Conversely, the P2RY6 receptor <span style="background-color:#FFA07A">antagonists</span>, anthraquinone-sulfonic acid derivative reactive blue 2 and suramin, inhibited <span style="background-color:#FFFF00">LPS</span>-<span style="background-color:#B0E0E6">induced</span> <span style="background-color:#FFFF00">IL-8</span> <span style="background-color:#B0E0E6">production</span> by <span style="background-color:#FFDEAD">THP-1</span> cells [24]. |
|- | |- | ||
| | | | ||
{| cellpadding=4 cellspacing=2 | {| cellpadding=4 cellspacing=2 | ||
|- | |- | ||
| − | | <span style="color:#800000">'''LPS'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induced</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">production</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">THP-1</span> | + | | <span style="color:#800000">'''LPS'''</span> <span style="color:#000080">'''Positive_regulation'''</span> (<span style="color:#000080">induced</span>) of <span style="color:#000080">'''Gene_expression'''</span> (<span style="color:#000080">production</span>) of <span style="color:#800000">'''IL-8'''</span> in <span style="color:#808000">THP-1</span> associated with <span style="color:#FF0000">'''antagonist'''</span> |
|- | |- | ||
|} | |} | ||
| Line 446: | Line 446: | ||
| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2394514 PMC2394514] | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2394514 PMC2394514] | ||
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.35 |
! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance | ||
| − | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| | + | | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 0.19 |
|} | |} | ||
|- | |- | ||
Revision as of 12:28, 14 September 2012
|
|
|
|
|
Sentences Mentioned In
| Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
| Nonetheless, vitamin D3 pretreatment resulted in decreased LPS-induced IL-6 and IL-8 production and blocked NF? | |||||||||||||||
| |||||||||||||||
|
| B and IKK-2 impaired the CXCL8 expression this points to a TLR4 and NF-? | |||||||||||||||
| |||||||||||||||
|
| As expected, it should be pointed that LPS-induced IL-8 levels varied among COPD patients, suggesting that epithelial cell responsiveness to LPS cannot alone explain the complex inflammatory process of COPD. | |||||||||||||||
| |||||||||||||||
|
| Indeed, it was found that a constitutively active mutant of human TLR4, transfected into a monocytic cell line, could induce the activation of NF-kappaB and the expression of the proinflammatory cytokines IL-1, IL-6, and IL-8 as well as the expression of the costimulatory molecule CD80 (B7.1), which is required for the activation of naïve T lymphocytes [66]. | |||||||||||||||
| |||||||||||||||
|
| Indeed, it was found that a constitutively active mutant of human TLR4, transfected into a monocytic cell line, could induce the activation of NF-kappaB and the expression of the proinflammatory cytokines IL-1, IL-6, and IL-8 as well as the expression of the costimulatory molecule CD80 (B7.1), which is required for the activation of naïve T lymphocytes [66]. | |||||||||||||||
| |||||||||||||||
|
| Conversely, the P2RY6 receptor antagonists, anthraquinone-sulfonic acid derivative reactive blue 2 and suramin, inhibited LPS-induced IL-8 production by THP-1 cells [24]. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.
